Stent Type Immaterial in TWILIGHT

]]>(MedPage Today) -- High-risk patients enjoyed a consistent benefit of ticagrelor (Brilinta) monotherapy after stenting, irrespective of which drug-eluting stent (DES) type was used, according to a prespecified analysis of the TWILIGHT trial.Compared...